Form 4: BridgeBio CEO Neil Kumar Reports RSU Conversions

BridgeBio Pharma CEO Neil Kumar reported the conversion of Restricted Stock Units into common stock and subsequent tax-related share disposals.

Summary

• Neil Kumar, CEO and Director of BridgeBio Pharma, Inc. (BBIO), reported transactions involving the company's common stock and Restricted Stock Units (RSUs).
• On February 16, 2026, Kumar acquired a total of 64,698 shares of common stock through the conversion of RSUs (33,544, 19,600, and 11,554 shares respectively).
• Concurrently, 30,970 shares of common stock were disposed of at a price of $75.25 per share to satisfy tax obligations related to the vesting of 64,698 RSUs.
• Following these transactions, Kumar directly beneficially owns 262,504 shares of common stock.
• Indirect beneficial ownership includes 675,686 shares via the Kumar Haldea Family Irrevocable Trust and 4,478,447 shares via the Kumar Haldea Revocable Trust, for which Kumar disclaims beneficial ownership except to the extent of his pecuniary interest.
• Remaining derivative securities include 134,176, 156,794, and 138,645 Restricted Stock Units, which vest quarterly subject to continued service.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, representing routine insider transactions related to executive compensation and tax obligations, with no direct positive or negative implications for the company's operational or financial outlook.

Positives

• The vesting of Restricted Stock Units indicates continued service and alignment of the CEO's interests with long-term company performance.
• The acquisition of common stock through RSU conversions increases the CEO's direct equity stake in the company.

Negatives

• A portion of the vested shares (30,970 shares) was disposed of to cover tax liabilities, which is a common practice but represents a reduction in direct holdings.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions and do not typically provide insights into broader industry trends or competitive positioning. These transactions reflect routine compensation and tax management for executives.

Related Party Transactions

• Indirect beneficial ownership of common stock through the Kumar Haldea Family Irrevocable Trust and the Kumar Haldea Revocable Trust, for which the Reporting Person is a co-trustee.

Stakeholder Impact

• Shareholders: The transactions are routine and reflect the compensation structure for the CEO, aligning his interests with long-term shareholder value through equity ownership.

Next Steps

• Continued quarterly vesting of remaining Restricted Stock Units, subject to the Reporting Person's continued service with the Issuer.

Key Dates

Keywords

BridgeBio Pharma, BBIO, Neil Kumar, Restricted Stock Units, RSU conversion, insider transaction, Form 4, common stock, tax withholding, beneficial ownership